Publications by authors named "V F Strand"
Objective: This study aimed to expand the understanding of the patient with psoriatic arthritis (PsA) experience and to compare/contrast patient and clinician prioritization of PsA dimensions.
Methods: We conducted four patients with PsA focus groups across three US rheumatology practices using mixed methods to identify attributes of PsA important to patients. Combination with extant attributes of PsA identified by a steering committee created a comprehensive list of attributes.
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023.
Objective: This post hoc analysis compared the immunogenicity of the biosimilar adalimumab-adbm (Cyltezo) with the adalimumab reference product (RP; Humira) across indications, including rheumatoid arthritis (RA), Crohn's disease (CD) and plaque psoriasis (PsO), and by patient sex in the VOLTAIRE trials programme.
Methods: In each active-comparator randomised controlled trial (RCT), immunogenicity was assessed at various time points by the proportion of patients with antidrug antibodies (ADAs) and neutralising antibodies (nAbs), using acid dissociation followed by electrochemiluminescence assay. Assay sensitivity was 50 ng/mL, and drug tolerance was ≥30 µg/mL (free drug) at the low positive control level.
Article Synopsis
- The VOLTAIRE-RA trial compared the efficacy and safety of a biosimilar adalimumab (Cyltezo) with the original adalimumab (Humira) in patients with rheumatoid arthritis.
- Participants were monitored for 24 weeks, with patient-reported outcomes evaluated at 12 and 24 weeks to determine the impact on their quality of life.
- Results showed that both treatment groups experienced significant improvements in health-related quality of life, with a high percentage of participants reporting greater improvements compared to a matched US population, highlighting a successful treatment outcome.